A phase II efficacy and safety study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer.
Ju‐Dong Li(Second Military Medical University), Lee Li(Guangxi Medical University), Yuping Sun(Shandong University), Liqing Li(Central South University), Xiangyang Zhu(Anhui Jianzhu University), Xiujie Sheng(Guangzhou Medical University), Wei Wei(Zhujiang Hospital), Chang Liu(Harbin Medical University), Ziyi Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiu-Min Li(Westchester Medical Center), Yi Huang(Tongji Hospital), Xiuqiang Ma(Second Military Medical University), Jinmei Yu(Jiangxi Maternal and Child Health Hospital), Hao Yu(University of Science and Technology Beijing), Li Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Xin Zhang(Shenyang First People's Hospital), Hongying Yang(Kunming Medical University), Qiao Zhu(Shandong University), Yuanhuan Xiong(Jiangxi Provincial People's Hospital), Junwei Gao(Jiangxi Provincial Cancer Hospital)
Cited by 4
Related Papers
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
SIRT1 Activators Suppress Inflammatory Responses through Promotion of p65 Deacetylation and Inhibition of NF-κB Activity
|PLoS ONE|2012|367
Development of Nano-Sulfide Sorbent for Efficient Removal of Elemental Mercury from Coal Combustion Fuel Gas
|Environmental Science & Technology|2016|285
Experimental and DFT study on the adsorption of VOCs on activated carbon/metal oxides composites
|Chemical Engineering Journal|2019|239
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217